SNHG15

Summary

SNHG15 (small nucleolar RNA host gene 15, HGNC:27797) is a long non-coding RNA gene on chromosome 7p13.

This gene represents a snoRNA host gene that produces a short-lived long non-coding RNA. This non-coding RNA is upregulated in tumor cells and may contribute to cell proliferation by acting as a sponge for microRNAs.

Source: NCBI Gene 285958 — RefSeq curated summary.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:27797
Approved symbol	SNHG15
Name	small nucleolar RNA host gene 15
Location	7p13
Locus type	RNA, long non-coding
Status	Approved
Aliases	FLJ38860, MYO1GUT, Linc-Myo1g
Ensembl gene	ENSG00000232956
Ensembl biotype	lncRNA
Entrez	285958
RNAcentral	URS0000CCE070 — lncRNA, 860 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 15 lncRNA

ENST00000438705, ENST00000577700, ENST00000578968, ENST00000579383, ENST00000580458, ENST00000580528, ENST00000582727, ENST00000584327, ENST00000584686, ENST00000585030, ENST00000653305, ENST00000667119, ENST00000667823, ENST00000668580, ENST00000720292

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000438705 — 3 exons

Exon	Start	End
ENSE00002721630	44983023	44983322
ENSE00002722982	44983822	44984046
ENSE00004038819	44986525	44986672

Expression profiles

Bgee: expression breadth ubiquitous, 221 present calls, max score 94.26.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 50.8815 / max 1505.8690, expressed in 1804 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
83923	48.0416	1803
83924	1.2014	488
83922	0.9810	426
83920	0.2424	106
83925	0.1391	45
83921	0.1325	74
83918	0.0994	30
83919	0.0440	14

Top tissues by expression

245 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	94.26	gold quality
left uterine tube	UBERON:0001303	93.07	gold quality
omental fat pad	UBERON:0010414	92.25	gold quality
peritoneum	UBERON:0002358	92.24	gold quality
tibial nerve	UBERON:0001323	91.40	gold quality
left ovary	UBERON:0002119	91.16	gold quality
adipose tissue of abdominal region	UBERON:0007808	91.13	gold quality
lower esophagus mucosa	UBERON:0035834	91.05	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	90.84	gold quality
upper lobe of left lung	UBERON:0008952	90.65	gold quality
right ovary	UBERON:0002118	90.49	gold quality
cortical plate	UBERON:0005343	90.39	gold quality
skin of abdomen	UBERON:0001416	90.13	gold quality
monocyte	CL:0000576	89.93	gold quality
esophagus mucosa	UBERON:0002469	89.92	gold quality
right lobe of thyroid gland	UBERON:0001119	89.77	gold quality
left lobe of thyroid gland	UBERON:0001120	89.77	gold quality
leukocyte	CL:0000738	89.76	gold quality
upper lobe of lung	UBERON:0008948	89.62	gold quality
cartilage tissue	UBERON:0002418	89.54	gold quality
cerebellar hemisphere	UBERON:0002245	89.27	gold quality
spleen	UBERON:0002106	89.25	gold quality
right hemisphere of cerebellum	UBERON:0014890	89.18	gold quality
prefrontal cortex	UBERON:0000451	89.10	gold quality
ovary	UBERON:0000992	89.07	gold quality
cerebellar cortex	UBERON:0002129	89.07	gold quality
skin of leg	UBERON:0001511	88.92	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	88.88	gold quality
ectocervix	UBERON:0012249	88.83	gold quality
thyroid gland	UBERON:0002046	88.76	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 34)

• Our findings present that elevated lncRNA SNHG15 could be identified as a poor prognostic biomarker in GC and regulate cell invasion. (PMID:26662309)
• SNHG15 and miR-153 are new potential therapeutic targets for anti-angiogenesis treatment of glioma (PMID:29048682)
• Long noncoding RNA SNHG15 was highly expressed in breast cancer tissues and cell lines. SNHG15 knockdown significantly inhibited the proliferation and induced apoptosis in breast cancer cells in vitro and in vivo. In mechanism, we found that SNHG15 acted as a competing endogenous RNA to sponge miR-211-3p, which was downregulated in breast cancers and inhibited cell proliferation and migration. (PMID:29217194)
• Results show that enhanced expression of lncRNA SNHG15 promoted colon cancer cell progression and was correlated with poor prognosis in colon cancer patients. Mechanistically, SNHG15 maintains Slug stability in living cells by impeding its ubiquitination and degradation through interaction with the zinc finger domain of Slug. (PMID:29604394)
• the present study suggested that SNHG15 may be involved in the nuclear factorkappaB signaling pathway, induce the epithelialmesenchymal transition process, and promote renal cell carcinoma invasion and migration. (PMID:29750422)
• The expression of SNHG15 is up-regulated on non-small lung cancer cells, promoting promotes cell proliferation and invasion. (PMID:29771418)
• SNHG15 levels were significantly up-regulated in both sera and tumors tissues from pancreatic ductal adenocarcinoma (PDAC) patients. Clinicopathologic analysis revealed that high SNHG15 expression was associated with tumor differentiation, lymph node metastasis, tumor stage and shorter overall survival. Cox multivariate analyses confirmed that SNHG15 expression was an independent prognostic factor in PDAC. (PMID:30280769)
• Lnc-SNHG15 overexpression was significantly associated with colorectal liver metastasis and poor survival. (PMID:30317592)
• SNHG15 is highly expressed in lung cancer (LC) tissues, which promotes the occurrence and progression of LC via regulating proliferation and migration of LC cells by targeting microRNA-211-3p. (PMID:30402848)
• Overexpression of lncSNHG15 remarkably promoted the proliferation and migration of non-small cell lung cancer cells. lncSNHG15 could bind to miR-211-3p. (PMID:30840276)
• SNHG15 served as a ceRNA and reversed the activity of miR-338-3p, thus facilitating CRC tumorigenesis by enhancing the expression of FOS and RAB14. (PMID:30945457)
• Results show that SNHG15 is upregulated in prostate cancer (PCa) cells and promoted cell proliferation. Its downregulation inhibited PCa cell migration and invasion. SNHG15 was located in the cytoplasm of PCa cells and acted as a molecular sponge of miR-338 resulting in post-transcriptional regulated FKBP1A. These study suggested that SNHG15 functions as an oncogene by modulating miR-338/FKBP1A axis in prostate cancer. (PMID:30981837)
• Several of these genes are functionally related to AIF, a protein that we found to specifically interact with SNHG15, suggesting that the SNHG15 acts, at least in part, by regulating the activity of AIF. (PMID:31014355)
• LncRNA SNHG15 promotes hepatocellular carcinoma progression by sponging miR-141-3p. (PMID:31310393)
• Up-regulation of SNHG15 was found in hepatocellular carcinoma (HCC) and was related to aggressive behaviors in HCC patients. Knockdown of SNHG15 restrained HCC cell proliferation, migration and invasion. SNHG15 served as a molecular sponge for miR-490-3p which directly targets HDAC2. HDAC2 was involved in HCC progression by interacting with the SNHG15/miR-490-3p axis. (PMID:31636472)
• Elevated expression of lncRNA SNHG15 in spinal tuberculosis: preliminary results. (PMID:31696491)
• LncRNA SNHG15 may serve as a prospective and novel biomarker for molecular diagnosis and therapeutics in patients with cancer. (PMID:31774607)
• Up-regulation of SNHG15 facilitates cell proliferation, migration, invasion and suppresses cell apoptosis in breast cancer by regulating miR-411-5p/VASP axis. (PMID:32141559)
• Long non-coding RNA SNHG15 is a competing endogenous RNA of miR-141-3p that prevents osteoarthritis progression by upregulating BCL2L13 expression. (PMID:32247266)
• High lncSNHG15 expression may predict poor cancer prognosis: a meta-analysis based on the PRISMA and the bio-informatics analysis. (PMID:32633324)
• LncRNA SNHG15 promotes the proliferation of nasopharyngeal carcinoma via sponging miR-141-3p to upregulate KLF9. (PMID:32633365)
• Long Non-Coding RNA (lncRNA) Small Nucleolar RNA Host Gene 15 (SNHG15) Alleviates Osteoarthritis Progression by Regulation of Extracellular Matrix Homeostasis. (PMID:32643707)
• LncRNA SNHG15 regulates EGFR-TKI acquired resistance in lung adenocarcinoma through sponging miR-451 to upregulate MDR-1. (PMID:32655137)
• Long noncoding RNA small nucleolar RNA host gene 15 deteriorates liver cancer via microRNA-18b-5p/LIM-only 4 axis. (PMID:33372376)
• The Expression of the Cancer-Associated lncRNA Snhg15 Is Modulated by EphrinA5-Induced Signaling. (PMID:33572758)
• LncRNA SNHG15 modulates gastric cancer tumorigenesis by impairing miR-506-5p expression. (PMID:33899079)
• Down-regulation LncRNA-SNHG15 contributes to proliferation and invasion of bladder cancer cells. (PMID:34016097)
• Increased serum exosomal long non-coding RNA SNHG15 expression predicts poor prognosis in non-small cell lung cancer. (PMID:34551140)
• lncRNA SNHG15 Promotes Ovarian Cancer Progression through Regulated CDK6 via Sponging miR-370-3p. (PMID:34734088)
• LncRNA SNHG15 Promotes Oxidative Stress Damage to Regulate the Occurrence and Development of Cerebral Ischemia/Reperfusion Injury by Targeting the miR-141/SIRT1 Axis. (PMID:34868528)
• LncRNA SNHG15 Modulates Ischemia-Reperfusion Injury in Human AC16 Cardiomyocytes Depending on the Regulation of the miR-335-3p/TLR4/NF-kappaB Pathway. (PMID:35650158)
• SNHG15 promotes chemoresistance and glycolysis in colorectal cancer. (PMID:37148838)
• SNHG15 promotes gallbladder cancer progression by enhancing the autophagy of tumor cell under nutrition stress. (PMID:37937948)
• Uncovering the relationship between YAP/ WWTR1 (TAZ) genes expression and LncRNAs of SNHG15, HCP5 and LINC01433 in breast cancer tissues. (PMID:38599044)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.